^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Malignant Pleural Mesothelioma
    Drug:Cyramza (ramucirumab) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    12/15/2022
    Excerpt:
    Mesothelioma: Pleural...Subsequent Systemic Therapy...Other recommended...Gemcitabine + ramucirumab added as a treatment option
    Secondary therapy:
    gemcitabine
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    Recommendations...Systemic therapy for second line and beyond…Single-agent gemcitabine or vinorelbine [II, B] have limited second-line activity, as suggested by ORRs or OS, with encouraging activity for gemcitabine–ramucirumab combination [III, C].
    Secondary therapy:
    gemcitabine
    DOI:
    https://doi.org/10.1016/j.annonc.2021.11.005